Compare
XBiotech Inc. vs Whitehawk Therapeutics, Inc. vs Veradermics, Inc vs Larimar Therapeutics, Inc.
| Latest fiscal year | XBiotech Inc. XBIT | Whitehawk Therapeutics, Inc. WHWK | Veradermics, Inc MANE | Larimar Therapeutics, Inc. LRMR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.14M | n/a | n/a |
| Revenue growth (YoY) | n/a | -72.5% | n/a | n/a |
| Gross margin | n/a | 89.4% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | -288.3% | n/a | n/a |
| Net income | -$45.54M | -$20.60M | -$70.00M | -$165.67M |
| EPS (Diluted) | -$1.49 | -$0.33 | -$111.91 | n/a |
| Operating cash flow | -$39.92M | -$97.43M | -$71.60M | -$113.20M |
| Free cash flow | -$40.21M | -$97.98M | -$71.63M | -$113.29M |
| Cash & equivalents | $125.55M | $37.57M | $21.77M | $85.41M |
| Total assets | $150.08M | $150.83M | $152.62M | $145.84M |
| Total liabilities | $9.73M | $14.52M | $9.16M | $67.76M |
| Shareholders' equity | $140.35M | $136.31M | -$121.01M | $78.08M |
| Return on year-end equity | -32.4% | -15.1% | n/a | -212.2% |
| Shares outstanding | 30.49M | 47.15M | 749.8K | 83.09M |
Revenue, most recent five fiscal years
| Fiscal year | XBiotech Inc. | Whitehawk Therapeutics, Inc. | Veradermics, Inc | Larimar Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $7.14M Ended 2025-12-31 | n/a | $0 Ended 2019-12-31 |
| 1 year earlier | $4.01M Ended 2022-12-31 | $25.98M Ended 2024-12-31 | n/a | $0 Ended 2018-12-31 |
| 2 years earlier | $18.39M Ended 2021-12-31 | $24.35M Ended 2023-12-31 | n/a | $0 Ended 2017-12-31 |
| 3 years earlier | $44.00M Ended 2020-12-31 | $15.22M Ended 2022-12-31 | n/a | $0 Ended 2016-12-31 |
| 4 years earlier | $0 Ended 2019-12-31 | $14.00M Ended 2021-12-31 | n/a | $0 Ended 2015-12-31 |